Bicara Therapeutics (BCAX) Assets Average (2024 - 2026)

Bicara Therapeutics (BCAX) has 3 years of Assets Average data on file, last reported at $492.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average changed 0.35% year-over-year to $492.3 million; the trailing twelve-month figure through Mar 2026 stood at $492.3 million (changed 0.35% YoY), and the FY2025 full-year result was $470.5 million, up 26.48% from the prior year.
• Assets Average for Q1 2026 stood at $492.3 million, up from $427.8 million in the prior quarter.
• Across five years, Assets Average topped out at $517.1 million in Q4 2024 and bottomed at $427.8 million in Q4 2025.
• The 3-year median for Assets Average is $479.1 million (2025), against an average of $472.7 million.
• The widest annual swing landed in 2025, when Assets Average decreased 17.26%; it then fell 0.35% in 2026.
• A 3-year view of Assets Average shows it stood at $517.1 million in 2024, then retreated by 17.26% to $427.8 million in 2025, then advanced by 15.07% to $492.3 million in 2026.
• The last three Assets Average figures came in at $492.3 million (Q1 2026), $427.8 million (Q4 2025), and $439.1 million (Q3 2025), per Business Quant data.

Peer Comparison